Regulatory

Harbin Pharmaceutical plans to invest $300 million, but it’s not clear when the deal will close.

The July 31 warning letter reflects FDA's continuing concern over the marketing of CBD products—including supplements—to treat diseases like cancer and schizophrenia without agency drug approval.

As tariffs stack up, here's a view from the natural and organic heartland.

AHPA encourages Senate and House conferees to remove unnecessary restrictions that ban some convicted felons from engaging in hemp production.

Pure or highly concentrated caffeine sold in powder and liquid forms is considered a safety issue and has been linked to two deaths. Warning letters in 2015 and 2016 labeled the sales unlawful, but the new guidance details the prohibition.

Supporters call new hemp legislation a “dream wish list” for all things cannabis.

Organic businesses, trade groups and animal-rights organizations support OTA's lawsuit against the USDA for not implementing livestock standards

Enacting organic regulations for aquaculture would behoove producers, retailers, manufacturers and consumers of sustainably sourced seafood.

The supplement industry heads into the new year with forward momentum, but adequate funding for FDA's Office of Dietary Supplement Products is critical.